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Abstract. – OBJECTIVE: The outbreak of 
coronavirus disease 2019 (COVID-19) has affect-
ed the treatment of cancer patients, with particu-
lar regard to the management of both chemother-
apy and side effects. Chemotherapy-induced 
nausea and vomiting (CINV) are amongst the 
most troublesome side effects that impair pa-
tients’ adherence to treatments and their quality 
of life (QoL). NEPA (Akynzeo®), is an oral fixed-
dose combination of netupitant [a neurokinin-1 
receptor antagonist (NK1RA), 300 mg] and palo-
nosetron [(5-hydroxytryptamine (serotonin or 
5HT) type3 receptor antagonist (5HT3RA), 0.5 
mg] which has been shown to be effective in pre-
venting CINV. 
PATIENTS AND METHODS: This prospective 
study started before the outbreak of COVID-19 
and was carried out during the pandemic period. 
The aim was to evaluate the efficacy and safety 
of a single oral dose NEPA plus 12 mg of dexa-
methasone (DEX) in patients treated with Folfox-
iri plus Bevacizumab and Folfirinox. The patients 
were diagnosed with advanced colorectal can-
cer (CRC) or advanced pancreatic ductal adeno-
carcinoma (PDAC). They were divided into two 
groups: naïve patients and patients previous-
ly treated with serotonin receptor antagonists 
(5HT3-RA) and neurokin-1 receptor antagonists 
(NK1-RA). 
RESULTS: During the overall phase, the com-
plete response (CR) rate was 96.8% in naïve 
patients treated with Folfoxiri plus Bevaci-
zumab, and 94.6% in patients treated with Fol-
firinox. During the acute and delayed phases, 
the CR rate was 92.8% and 94.2%, with Folfoxiri 
and Bevacizumab, as well as 96.2% and 94.6%, 
with Folfirinox. There was no adequate control 
of CINV events in patients on antiemetic pro-
phylaxis with 5HT3-RA or NK1-RA associated 
with cortisone. During the overall phase, the CR 
rate was 74.6% with Folfoxiri plus Bevacizum-
ab and 75.8% with Folfirinox. During the acute 
and delayed phases, the CR rate was 72.5% and 
74.8% with Folfoxiri plus Bevacizumab, as well 
as 75.2% and 74.6% with Folfirinox. 
CONCLUSIONS: This study has shown the 
therapeutic benefits of NEPA in the manage-
ment and prophylaxis of CINV events, both in na-
ive patients and patients previously treated with 
5HT3-RA and NK1-RA. In addition, NEPA has 
been shown to be safe, both before and during 
the COVID-19 pandemic.
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Introduction
The highly infectious nature of the new coro-
navirus pandemic (COVID-19), and its wide-
spread prevalence, have created new obstacles 
in managing cancer patients1,2. As a result, new 
priorities – such as the execution of rapid swabs 
and the restriction of access into the wards – have 
been set in order to reduce the risk of contagion 
amongst patients with cancer. This strategy is also 
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valid for patients with side effects, such as nausea 
and vomiting, caused by emetizing chemothera-
py3. Chemotherapy-induced nausea and vomiting 
(CINV) events occur in approximately 60-70% 
of patients and are amongst the most feared side 
effects, along with alopecia4,5. The CINV onset 
depends on the emetogenic potential of chemo-
therapy, which varies in relation to drugs, doses 
and possible combinations6. Persistent nausea 
and vomiting cause dehydration with loss of nu-
trients and minerals, as well as anorexia with 
decreased intake of food and liquids. These con-
ditions worsen the patients’ health and compro-
mise their adherence to treatment and quality of 
life (QoL)7,8. Two neurotransmitters play a crucial 
role in mediating the emetic response: serotonin 
acting on the 5HT3 receptor and the substance P 
targeting the NK1 receptor. Several drugs9,10 are 
currently available for prophylaxis of nausea and 
vomiting caused by antineoplastic treatments. 
However, most effective ones belong to the class 
of 5HT3 receptor antagonists (5HT3-RAs) or to 
the NK1 receptor antagonists (NK1-RAs). New 
treatments for advanced colorectal cancer (CRC) 
and advanced pancreatic ductal adenocarcinoma 
(PDAC) include three drug regimens, Folfoxiri 
plus Bevacizumab and Folfirinox. Such drugs in-
duce nausea and vomiting that standard antiemet-
ics cannot adequately control. It has been recently 
shown that an oral combination of a 5HT3 recep-
tor antagonist (5HT3-RA) and an NK1 receptor 
antagonist (NK1-RA), together with dexameth-
asone, is highly effective11,12. Netupitant 300 mg 
and Palonosetron 0.5 mg (NEPA) has been devel-
oped for CINV prophylaxis13,14. This simultaneous 
action mechanism, of two anti-emetic pathways, 
combines into a single administration of NEPA. 
As a result, the protection against CINV events 
is effective, safe and longer-lasting15. NEPA (net-
upitant/palonosetron) is the only fixed-dose com-
bination of antiemetics currently available. It is 
composed of the long-lasting second-generation 
palonosetron (5HT3-RA) and the highly selec-
tive netupitant (NK1-RA)16,17. The present study 
aimed to evaluate the efficacy and safety of a sin-
gle dose NEPA plus 12 mg DEX in CINV pro-
phylaxis, during the treatment with Folfoxiri plus 
Bevacizumab and Folfirinox, for CRC and PDAC, 
both in naïve patients and in patients previously 
treated with 5HT3-RA. This prospective study, 
conducted before and during the COVID-19 pan-
demic, evaluated the complete response rate (CR), 
any vomiting events. It also considered the use of 
rescue medication during the overall phase (0-120 
h), after the first cycle of chemotherapy and sub-
sequent ones. The secondary endpoints were CR 
rates during the acute (0-24 h) and delayed (25-
120 h) phases. During the acute, delayed, overall 
phase and QoL, no nausea was assessed. In re-
sponse to COVID-19, preventive measures have 
been taken. These included swabs for patients and 
the building of a multidisciplinary team of gen-
eral practitioners, psychologists, and healthcare 
professionals. The main aims were to optimize 
the results in this challenging time and restrict 




This prospective study was conducted before 
and during the COVID-19 pandemic in full com-
pliance with the provisions of the Declaration of 
Helsinki. These were communicated to the Pal-
ermo 1 Ethics Committee, and all patients pro-
vided written informed consent to the treatment. 
Between March 2017 and December 2020, one 
hundred consecutive patients were inserted at 
Oncology Department of University Palermo. El-
igibility criteria included: histological or cytolog-
ical diagnosis of CRC or PDAC; locally advanced 
or metastatic disease that can be measured and 
evaluated in accordance with Response Evalua-
tion Criteria in Solid Tumors (RECIST) version 
1.1; performance status score between 0 and 1 
according to the Eastern Cooperative Oncology 
Group (ECOG); adequate hematologic, renal, and 
liver function. Ineligibility criteria included hy-
persensitivity to NEPA or its constituents and oth-
er drugs used. The patients were divided into two 
groups according to their oncological pathology. 
In the first group, 50 patients with advanced CRC 
were treated with Folfoxiri plus Bevacizumab, ev-
ery 15 days, for eight cycles. In the second group, 
50 patients with advanced PDAC were treated 
with Folfirinox every 15 days for eight cycles. 
Method of Administration
A capsule of NEPA (300 mg/0.5 mg) along 
with dexamethasone (12 mg) was administered 
approximately an hour before chemotherapy, 
on day one of each cycle (every 15 days)20. Any 
episode of nausea and vomiting was assessed in 
compliance with the Common Terminology Cri-
teria for Adverse Events (CTCAE) v5.0. Clinical 
evaluations, as well as physical tests and labora-
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tory studies, were carried out to monitor tolera-
bility. In order to avoid coronavirus (COVID-19) 
infection, patients were asked to comply with 
mandatory rules, such as: a) avoid crowded plac-
es; b) wear PPE when going to the hospital for ex-
aminations or treatments; c) wash hands properly, 
in compliance with the instructions provided by 
the World Health Organization (WHO); d) avoid 
any contact with friends and relatives who have 
COVID-19 symptoms or live in endemic areas; e) 
ensure social distancing with other people: “pro-
tect yourself to protect others”. In addition, it was 
built a multidisciplinary team of general practi-
tioners, psychologists, and health professionals. 
The main aims were to optimize results in this 
difficult time and restrict patients’ access to the 
departments, where the risk of contagion is high.
Outcomes 
Following the outbreak of the global pandemic 
of COVID-19, managing patients enrolled in this 
study has required new measures to reduce the 
risk of exposure to the virus. In order to restrict 
access to the wards, patients interacted with hos-
pital staff by telephone.
Patients were asked to complete a self-assess-
ment diary of nausea, recording any vomiting 
episodes that occurred from day one to day sev-
en after chemotherapy. Each episode was clas-
sified according to the Likert scale (none, mild/
moderate or severe). The European Organization 
for Research and Treatment of Cancer (EORTC) 
QLQ-C30 questionnaire21 was provided to assess 
QoL at baseline and after eighth cycles. The ques-
tionnaire consists of 30 items on a 4-point Likert 
scale (1 = “No”; 4 = “a lot”). A high score indicates 
a high level of response, whereas a high score on a 
physical symptoms scale indicates a higher num-
ber of health issues. The association between the 
overall CR and CINV events was analyzed using 
the Bravais-Pearson (r) linear correlation index. 
All analyses were conducted using SAS version 
9.4 (SAS Institute, Cary, NC, USA).
Results
Patients Characteristic
During the COVID-19 pandemic, the collab-
oration between teams of local specialists has 
refrained many patients from accessing the hos-
pitals, reducing the risk of contagion. All staff ac-
cessing the oncology wards have been screened, 
and the use of face masks is mandatory. All of 
one hundred patients have completed the eight cy-
cles arranged. In the first group, amongst the 50 
patients enrolled, 22 were females and 28 males, 
with a median age of 58 years. In the second 
group, 24 patients out of 50 were females and 26 
males, with a median age of 62 years. 
In the first group: 25 patients (11 females and 14 
males) received NEPA plus 12 mg of DEX for each 
of the eight cycles agreed. The other 25 patients 
(13 females and 12 males) randomly received either 
5HT3-RA or NK1-RA for the first four cycles and 
NEPA plus 12 mg of DEX for the last four cycles.
In the second group: 25 patients (12 females 
and 13 males) received NEPA plus 12 mg of DEX 
for each of the eight cycles agreed. The other 25 
patients (12 females and 13 males) were randomly 
given either 5HT3-RA or NK1-RA for the first 
four cycles and NEPA plus 12 mg of DEX for the 
remaining four cycles. The patients’ clinical and 
pathological characteristics are shown in Table I.
Response Rate 
During overall phase the CR in naïve patients 
who received Folfoxiri plus Bevacizumab, was 
96.8% and 94.6% in patients who received Folf-
irinox. During the acute and delayed phases, the 
CR rate was 92.8% and 94.2% in patients who 
were administered Folfoxiri and Bevacizumab. In 
patients who received Folfirinox, the CR rate was 
96.2% and 94.6% (Figure 1 and Figure 2). These 
responses were maintained throughout the sub-
sequent cycles. Control of nausea raised as well, 
with NSN rates > 90% (Figure 3 and Figure 4) 
and no home rescue medication (metoclopramide/
cortisone) was required. Appetite and nutrition 
remained substantially unchanged. 
The patients treated for the first four cycles 
with standard antiemetic therapy (5HT3-RA and 
NK1-RA) did not have adequate control of CINV. 
During the overall phase the CR was 74.6% with 
Folfoxiri plus Bevacizumab and 75.8% with Fol-
firinox (Figure 1 and Figure 2).  These responses 
remained the same even during subsequent cycles. 
During the acute and delayed phase, the CR was 
72.5% and 74.8% with Folfoxiri and Bevacizum-
ab. It was 75.2% and 74.6% with Folfirinox (Fig-
ure 1 and Figure 2). Control of nausea decreased 
significantly, with an NSN rate of 50%. Nausea 
was more frequently detected in females, whereas 
amongst all patients, the grade was predominant-
ly G-2 (Figure 3 and Figure 4). Appetite and nu-
trition decreased due to nausea with weight loss, 
fatigue and adynamia. Metoclopramide 10 mg 
was the most frequent rescue drug taken. Finally, 
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patients initially treated with 5HT3-RA and NK1-
RA and switching to NEPA plus 12 mg of DEX 
after the first four cycles immediately showed an 
improvement in CINV events control. During the 
overall phase, the CR rate was 88.6% with Folfox-
iri plus Bevacizumab and 89.2% with Folfirinox. 
During the acute and the delayed phases, the CR 
rate was 89.5% and 88.6% with Folfoxiri plus Bev-
acizumab and 88.6% and 89.4% with Folfirinox 
(Figures 1 and Figure 2). These CR rates remained 
Figure 1. CR during acute (0-24 h), delayed (25-120 h) and overall (0-120 h) phase in CRC patients with Folfoxiri plus Beva-
cizumab treatment (n. 50). Note: CR = Complete response (no vomiting and no rescue medication); CRC = Colorectal cancer.
Table I. Clinical characteristics of patients’ 1st group with CRC (n. 50) in treatment Bevacizumab with Folfoxiri and 2nd group 
with PC (n. 50) in treatment with Folfirinox.s.
Characteristics Patients 1st group Patients 2nd group
Mean age [range] years 58 [45-66] 62 [48-75]
Gender 
  Male 56 % (28) 48% (24)
  Female 44% (22) 52% (26)
 
ECOG performance status 
  0 64% (32).   88% (44)
  1 36% (18). 2% (6)
Primary tumor location  
  Colon  Pancreas
  Single left-site 32% (16) Head 50% (25)                     
  Single right-site  68% (34) Body 36% (18)
  Tail 14% (7)
K-RAS status 
  Mutated 78% (34)  
  Wilde type 22% (11)
Location of metastasis
  Liver 12% (6) 8% (4)
  Lung 2% (1) 0% (-)
  Peritoneum  12% (6) 6% (3)
  Locally advanced not operable ab initio 74% (39 86% (43) 
Note: ECOG = Eastern Cooperative Oncology Group; CRC = Colorectal cancer; PC = Pancreatic cancer.
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Figure 2. CR during acute (0-24 h), delayed (25-120 h) and overall (0-120 h) phase in CP patients with Folfirinox treatment 
(No. 50). Note: CR = Complete response (no vomiting and no use of rescue medication); PC = Pancreas cancer. 
Figure 3. No nausea during the acute (0-24 h), delayed (25-120 h), and overall phase (0-120 h) in Folfoxiri plus Bevacizumab 
chemotherapy (No. 50).
Table II. Average scores EORTC QLQ C-30 before and 
after treatment with Paired Samples Test (No. 100).
 Mean SD t p
Global Health QLQ 30.1 6.59
 (pre-treatment)
Global Health QLQ 58.7  7.31 11.90 0.005
 (post-treatment)
Note: EORTC QLQ C-30 = European Organization for Re-
search and Treatment of Cancer.
high in the subsequent cycles. Control of nausea 
significantly increased with an NSN rate >80%. 
(Figures 3 and Figure 4). Very few patients (3-4%) 
resorted to rescue drugs (metoclopramide / corti-
sone). Appetite and weight gain have increased.
Safety
The antiemetic treatment with NEPA was well 
tolerated and with no evidence of increased ad-
verse events (AEs) in both naïve and in pretreat-
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ed patients. Adverse events reported by the three 
groups of patients were those expected for the 
5HT3RA and NK1RA agents. No patient dis-
continued the treatment due to side effects, and 
there were no unexpected serious adverse events 
that could be attributed to the antiemetic regi-
men. The most frequent adverse events included 
headache, fatigue, and constipation. No patients 
showed symptoms or signs of either neurotoxicity 
or significant ECG changes. NEPA has not shown 
effects on QT to ECG.  No G-4 toxicity led to the 
discontinuation of the treatment. Last follow-up 
has been done in March 2021.
Quality of Life
An improvement in QoL was also observed in 
58% of patients. On the symptom scale of the EO-
RTC-QLQ-C30 questionnaire, nausea and vomit-
ing have a median score of 48.7 (DS 22.6) in the 
pre-treatment period, whereas, after the treatment 
with NEPA, the median score was 31.2 (DS 18.8). 
The results showed that drug management highly 
reduces symptoms, improving patients’ general 
health. In approximately 45-52% of patients, nau-
sea does not impact daily life (Table II).
Discussion
CINV events are amongst the most feared side 
effects in cancer patients who receive chemo-
therapy. They compromise patients’ adherence to 
treatments and have a negative impact on QoL22,23. 
Despite pharmacological prophylaxis, ~61% of 
patients experience CINV (34% acute, 58% de-
layed), while undergoing moderately or highly 
emetogenic chemotherapy (MEC and HEC)24. 
During the COVID-19 pandemic, it was essential 
to manage chemotherapy-induced adverse events 
at home, when possible. This study has shown the 
efficacy and tolerability of NEPA in patients with 
a high risk of CINV who received emetogenic 
chemotherapy with Folfoxiri plus Bevacizumab 
in advanced CRC, and Folfirinox in advanced 
PDAC25,26. Compared to standard antiemet-
ic treatments (5HT3-RA and NK1-RA), NEPA 
achieved superior efficacy in all primary and sec-
ondary endpoints during the acute, delayed and 
general phases, including QoL. Furthermore, the 
efficacy of NEPA was maintained in those pa-
tients who had previously received a CINV pro-
phylaxis with standard antiemetics (5HT3-RA or 
NK1-RA). The results have shown that NEPA is 
widely superior to standard antiemetics. Most im-
portantly, when used after failing treatment with 
5HT3-RA or NK1-RA, it does not lose its effec-
tiveness, achieving the same CINV control rate as 
that achieved in naive patients27,28. These patients 
resumed eating and gained weight. Therefore, 
NEPA might be the best indication for patients in 
poor general health condition who undergo high-
ly-emetic anticancer therapy. In addition, the data 
showed that the control of CINV events remained 
constant over the subsequent cycles29. NEPA has 
Figure 4. No nausea during the acute (0-24 h), delayed (25-120 h), and overall phase (0-120 h) in Folf-
irinox chemotherapy (No. 50).
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been shown to be effective and safe in prevent-
ing chemotherapy-induced emesis. As a result, 
adherence to cancer treatments has increased 
with survival benefits and a higher level of QoL. 
The highly infectious nature and the widespread 
prevalence of COVID-19 have led to significant 
changes in managing cancer patients, which has 
become very complicated with the outbreak of 
the pandemic. Patients, or their caregiver, were 
reached by phone to monitor any side effects oc-
curred, and when required, dose-reduction was 
performed to manage the DRT better. Precau-
tionary measures have been taken, such as the 
delay of the post-treatment surveillance check-up 
and the increase of the treatment period between 
courses of systemic palliative therapy. This study 
has shown that during the COVID 19 pandemic, 
the use of NEPA as prophylaxis of CINV events 
has reduced the number of medical check-ups to 
clear up the complications of nausea and vom-
iting. The use of oral therapies, such as NEPA, 
to prevent the side effects induced by emetizing 
chemotherapy has allowed the hospital staff to 
restrict access to the wards, reducing the risk of 
contagion.
Conclusions
During the COVID-19 pandemic, while man-
aging cancer patients has become complicated, 
NEPA has proven to be efficacious in the prophy-
laxis of nausea and vomiting and in preventing all 
complications. Therefore, the number of patients 
who needed supportive care at the hospital, where 
the risk of coronavirus infection was high, has 
been significantly reduced. 
This study has shown that the use of NEPA 
plus 12 mg of DEX during chemotherapy with 
Folfoxiri and Folfirinox has improved the anti-
emetic control, compared to the results achieved 
with 5HT3-RA and NK1- RA30. These results 
have shown that NEPA could be a valid and ef-
fective antiemetic to treat patients who undergo 
highly emetogenic chemotherapy. NEPA has been 
proved to be highly effective and well-tolerated 
in preventing CINV events. Subsequentially, it 
has determined an increase in adherence to che-
motherapy and a higher QoL, especially during 
the COVID-19 pandemic. This study was carried 
out during the pandemic, which implied several 
inconveniences, such as a limited number of pa-
tients to enrol. Nevertheless, the results obtained 
are consistent with other studies, and they may 
provide a valid premise for future studies.
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